-
公开(公告)号:WO03020880A2
公开(公告)日:2003-03-13
申请号:PCT/US0224546
申请日:2002-08-02
Applicant: ABBOTT LAB , BORHANI DAVID W , CALDERWOOD DAVID , DIXON RICHARD W , HIRST GAVIN C , HRNCIAR PETER , LOEW ANDREAS , LEUNG ADELAINE , RITTER KURT
Inventor: BORHANI DAVID W , CALDERWOOD DAVID , DIXON RICHARD W , HIRST GAVIN C , HRNCIAR PETER , LOEW ANDREAS , LEUNG ADELAINE , RITTER KURT
CPC classification number: C12N9/1205 , C07K2299/00
Abstract: The present invention relates to polypeptides which comprise the ligand binding domain of Lck, crystalline forms of these polypeptides, and the use of these crystalline forms to determine the three dimensional structure of the catalytic domain of Lck. The invention also relates to the use of the three dimensional structure of the Lck catalytic domain both alone, or in complex with inhibitors, in methods of designing and/or identifying potential inhibitors of Lck activity, for example, compounds which inhibit the binding of a native substrate to the Lck catalytic domain. The invention also relates to the use of the three dimensional structure of the Lck catalytic domain both alone, or in complex with inhibitors, in methods of designing and/or identifying potential selective inhibitors of Lck activity, for example, compounds which inhibit the binding of a native substrate to the Lck catalytic domain selectively.
Abstract translation: 本发明涉及包含Lck的配体结合结构域,这些多肽的结晶形式的多肽以及使用这些结晶形式来确定Lck的催化结构域的三维结构。 本发明还涉及单独或与抑制剂复合的Lck催化结构域的三维结构在设计和/或鉴定潜在的Lck活性抑制剂的方法中的用途,例如抑制 天然底物到Lck催化结构域。 本发明还涉及单独或与抑制剂复合的Lck催化结构域的三维结构在设计和/或鉴定潜在的Lck活性选择性抑制剂的方法中的应用,例如抑制 选择性地将天然底物连接到Lck催化结构域。
-
公开(公告)号:EP1496910A4
公开(公告)日:2006-03-29
申请号:EP03718039
申请日:2003-03-21
Applicant: ABBOTT LAB
Inventor: HIRST GAVIN C , ARNOLD LEE D , BURCHAT ANDREW , WISHART NEIL , CALDERWOOD DAVID , WADA CAROL K , MICHAELIDES MICHAEL R , JI ZHIQIN , MUCKEY MELANIE
IPC: A61K31/519 , A61P1/04 , A61P1/16 , A61P3/10 , A61P5/14 , A61P7/00 , A61P7/06 , A61P9/00 , A61P9/10 , A61P9/12 , A61P11/00 , A61P11/06 , A61P13/12 , A61P15/08 , A61P17/02 , A61P17/06 , A61P19/02 , A61P27/02 , A61P27/06 , A61P29/00 , A61P31/04 , A61P31/12 , A61P31/18 , A61P31/22 , A61P33/02 , A61P35/00 , A61P35/02 , A61P37/02 , A61P37/06 , A61P43/00 , C07D413/04 , C07D487/04 , C07D491/04 , C07D491/048 , C07D498/04
CPC classification number: C07D487/04 , C07D491/04
-
公开(公告)号:PL373649A1
公开(公告)日:2005-09-05
申请号:PL37364903
申请日:2003-03-21
Applicant: ABBOTT LAB
Inventor: HIRST GAVIN C , ARNOLD LEE D , BURCHAT ANDREW , WISHART NEIL , CALDERWOOD DAVID , WADA CAROL K , MICHAELIDES MICHAEL R , JI ZHIQIN , MUCKEY MELANIE
IPC: A61K31/519 , A61P1/04 , A61P1/16 , A61P3/10 , A61P5/14 , A61P7/00 , A61P7/06 , A61P9/00 , A61P9/10 , A61P9/12 , A61P11/00 , A61P11/06 , A61P13/12 , A61P15/08 , A61P17/02 , A61P17/06 , A61P19/02 , A61P27/02 , A61P27/06 , A61P29/00 , A61P31/04 , A61P31/12 , A61P31/18 , A61P31/22 , A61P33/02 , A61P35/00 , A61P35/02 , A61P37/02 , A61P37/06 , A61P43/00 , C07D413/04 , C07D487/04 , C07D491/04 , C07D491/048 , C07D498/04 , C07D487/02
Abstract: The present application is directed to pyrazolopyrimidine and furopyrimnidine analogs of the formula (I) wherein the substituents are as defined herein, which are useful as kinase inhibitors.
-
公开(公告)号:ECSP10010657A
公开(公告)日:2011-02-28
申请号:ECSP10010657
申请日:2010-12-03
Applicant: ABBOTT LAB
Inventor: WOLLER KEVIN ROGER , WISHART NEIL , FRIEDMAN MICHAEL , CALDERWOOD DAVID , ARGIRIADI MARIA A , WALLACE GRIER A , ERICSSON ANNA M , FIAMENGO BRYAN A , FRANK KRISTINE E , GEORGE DAWN M , GOEDKEN ERIK R , JOSEPHSOHN NATHAN S , LI BIQIN C , MORYTKO MICHAEL J , STEWART KENT D , VOSS JEFFREY W , WANG LU
IPC: A01N43/42
Abstract: La invención proporciona un compuesto de la Formula (I)Formula (I)sales farmacéuticamente aceptables, metabolitos biológicamente activos, estereoisómeros eisómeros de estos en donde las variables están definidas en este documento. Los compuestos de la invención son útiles para el tratamiento de condiciones inmunológicas y oncológicas.
-
公开(公告)号:AU2003222055A1
公开(公告)日:2003-10-08
申请号:AU2003222055
申请日:2003-03-21
Applicant: ABBOTT LAB
Inventor: HIRST GAVIN C , ARNOLD LEE D , BURCHAT ANDREW , WISHART NEIL , CALDERWOOD DAVID , WADA CAROL K , MICHAELIDES MICHAEL R , JI ZHIQIN , MUCKEY MELANIE
IPC: A61K31/519 , A61P1/04 , A61P1/16 , A61P3/10 , A61P5/14 , A61P7/00 , A61P7/06 , A61P9/00 , A61P9/10 , A61P9/12 , A61P11/00 , A61P11/06 , A61P13/12 , A61P15/08 , A61P17/02 , A61P17/06 , A61P19/02 , A61P27/02 , A61P27/06 , A61P29/00 , A61P31/04 , A61P31/12 , A61P31/18 , A61P31/22 , A61P33/02 , A61P35/00 , A61P35/02 , A61P37/02 , A61P37/06 , A61P43/00 , C07D413/04 , C07D487/04 , C07D491/04 , C07D491/048 , C07D498/04 , C07D491/00 , C07D487/02 , C07D473/00 , C07D471/00 , C07D487/00
Abstract: The present application is directed to pyrazolopyrimidine and furopyrimnidine analogs of the formula (I) wherein the substituents are as defined herein, which are useful as kinase inhibitors.
-
公开(公告)号:CA2477651A1
公开(公告)日:2003-10-02
申请号:CA2477651
申请日:2003-03-21
Applicant: ABBOTT LAB
Inventor: BURCHAT ANDREW , ARNOLD LEE D , WADA CAROL K , HIRST GAVIN C , WISHART NEIL , CALDERWOOD DAVID , MICHAELIDES MICHAEL R , MUCKEY MELANIE , JI ZHIQIN
IPC: A61K31/519 , A61P1/04 , A61P1/16 , A61P3/10 , A61P5/14 , A61P7/00 , A61P7/06 , A61P9/00 , A61P9/10 , A61P9/12 , A61P11/00 , A61P11/06 , A61P13/12 , A61P15/08 , A61P17/02 , A61P17/06 , A61P19/02 , A61P27/02 , A61P27/06 , A61P29/00 , A61P31/04 , A61P31/12 , A61P31/18 , A61P31/22 , A61P33/02 , A61P35/00 , A61P35/02 , A61P37/02 , A61P37/06 , A61P43/00 , C07D413/04 , C07D487/04 , C07D491/04 , C07D491/048 , C07D498/04 , C07D473/00 , C07D491/00
Abstract: The present application is directed to pyrazolopyrimidine and furopyrimidine analogs of the formula (I), wherein the substituents are as defined herein, which are useful as kinase inhibitors.
-
公开(公告)号:AT419253T
公开(公告)日:2009-01-15
申请号:AT04779180
申请日:2004-07-26
Applicant: ABBOTT LAB
Inventor: BETSCHMANN PATRICK , BURCHAT ANDREW , CALDERWOOD DAVID , CURTIN MICHAEL , DAVIDSEN STEVEN , DAVIS HEATHER , FREY ROBIN , HEYMAN HOWARD , HIRST GAVIN , HRNCIAR PETER , MICHAELIDES MICHAEL , MUCKEY MELANIE , RAFFERTY PAUL , WADA CAROL
IPC: C07D495/04 , A61K31/4355 , A61K31/4365 , A61P35/00 , C07D491/04 , C07D498/04
Abstract: Compounds having the formula are useful for inhibiting protein tyrosine kinases. The present invention also discloses methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.
-
公开(公告)号:AU2002327422A1
公开(公告)日:2003-03-18
申请号:AU2002327422
申请日:2002-08-02
Applicant: ABBOTT LAB
Inventor: HIRST GAVIN C , RITTER KURT , LOEW ANDREAS , CALDERWOOD DAVID , HRNCIAR PETER , DIXON RICHARD W , BORHANI DAVID W , LEUNG ADELAINE
Abstract: The present invention relates to polypeptides which comprise the ligand binding domain of Lck, crystalline forms of these polypeptides, and the use of these crystalline forms to determine the three dimensional structure of the catalytic domain of Lck. The invention also relates to the use of the three dimensional structure of the Lck catalytic domain both alone, or in complex with inhibitors, in methods of designing and/or identifying potential inhibitors of Lck activity, for example, compounds which inhibit the binding of a native substrate to the Lck catalytic domain. The invention also relates to the use of the three dimensional structure of the Lck catalytic domain both alone, or in complex with inhibitors, in methods of designing and/or identifying potential selective inhibitors of Lck activity, for example, compounds which inhibit the binding of a native substrate to the Lck catalytic domain selectively.
-
公开(公告)号:CO6382083A2
公开(公告)日:2012-02-15
申请号:CO10150402
申请日:2010-11-29
Applicant: ABBOTT LAB
Inventor: WISHART NEIL , ARGIRIADI MARIA A , CALDERWOOD DAVID , ERICSSON ANNA M , FIAMENGO BRYAN , FRANK KRISTINE , GOEDKENT ERIC
IPC: A01N43/42
Abstract: La invención provee un compuesto de Fórmula (I)Sales, pro-fármacos, metabolitos activos biológicamente, estereoisómeros e isómeros aceptables farmacéuticamente del mismo en donde las variables se definen aquí. Los compuestos de la invención son útiles para tratamiento de condiciones inmunológicas y oncológicas.
-
-
-
-
-
-
-
-